Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $776K (cash outflow) fell 41.4% year over year, behind the +59.4% change in trailing-twelve-month financing cash flow. Sequentially, it rose 21.3% from the prior quarter.
Context
- Financing cash flow amounted to 1.3% of revenue in FY2025, up 1.3 pp from a year earlier.
- Financing cash flow increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -41.4% toward the trailing-twelve-month pace of +59.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (2.91M) USD
- Year-over-year change
- -1774.8%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.91M) | -1774.8% |
| FY2024 | 2024-12-31 | (155K) | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 734K | -79.3% |
| FY2021 | 2021-12-31 | 3.55M | — |
Financing Cash Flow vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's LTM Mar 2026 financing cash flow of $2.36M is the 8th largest of the 11 companies compared; the peer median is $20.68M.
- Its year-over-year change of +59.4% is the 7th highest of 11, against a peer median of +147.0%.
- Financing cash flow amounts to 1.1% of revenue for VNDA, versus a peer median of 11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $250.31M | +66.3% | +271.0% | — | |
| LTM Mar 2026 | $212.95M | +1074.3% | +2184.5% | — | |
| LTM Mar 2026 | $51.55M | +779.8% | +38.7% | — | |
| LTM Mar 2026 | $38.07M | -61.2% | — | 1888.3% | |
| LTM Mar 2026 | $37.29M | -71.1% | +117.0% | — | |
| LTM Mar 2026 | $25.14M | +10830.9% | — | — | |
| LTM Mar 2026 | $4.07M | +227.6% | -9.7% | 11.1% | |
| LTM Mar 2026 | $2.36M | +59.4% | — | 1.1% | |
| LTM Mar 2026 | $1.8M | -109.8% | — | 4.0% | |
| LTM Mar 2026 | $637K | -99.4% | +22.8% | 11.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $275K | +1118.5% | — | — |
| Peer median (excluding VNDA) | $20.68M | +147.0% | +77.9% | 11.1% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 33.15M | 6.28M | 2.51M | (18.9M) | (220.47M) |
| Depreciation & Amortization | 2.84M | 2.73M | 3.01M | 8.13M | (950K) |
| Deferred Income Tax | 6.75M | 1.13M | (1.29M) | (6.48M) | 81.44M |
| Stock-Based Compensation | 15.37M | 16.28M | 14.04M | 12.43M | 9.47M |
| Change in Working Capital | 2.74M | 6.07M | (747K) | (6.56M) | 8.31M |
| Accounts Receivables | (2.47M) | (1.09M) | (707K) | (13.01M) | (7.46M) |
| Inventory | (2.23M) | (4.48M) | (771K) | (29K) | (3.47M) |
| Accounts Payables | 3.04M | 11.79M | (10.98M) | 1.71M | 15.82M |
| Other Working Capital | 4.4M | (151K) | 11.72M | 4.78M | 3.42M |
| Other Non-Cash Items | 3.37M | (507K) | (4.73M) | (4.38M) | 12.76M |
| Operating Cash Flow | 64.21M | 31.98M | 12.8M | (15.76M) | (109.44M) |
| Capital Expenditures | (552K) | (679K) | (383K) | (490K) | (998K) |
| Acquisitions (Net) | 0 | 0 | (100.67M) | (4.23M) | 0 |
| Purchases of Investments | (420.46M) | (349.26M) | (512.61M) | (364.77M) | (112.38M) |
| Sales of Investments | 344.32M | 399.86M | 601.6M | 352.06M | 208.24M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (76.7M) | 49.93M | (12.06M) | (17.43M) | 94.86M |
| Debt Repayment | 0 | 0 | 0 | (155K) | (1.99M) |
| Common Stock Issued | 3.55M | 734K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (915K) |
| Financing Cash Flow | 3.55M | 734K | 0 | (155K) | (2.91M) |
| Effect of Forex Changes | (85K) | 315K | 47K | (163K) | 126K |
| Net Change in Cash | (9.02M) | 82.96M | 792K | (33.51M) | (17.36M) |
| Free Cash Flow | 63.66M | 31.31M | 12.42M | (16.25M) | (110.44M) |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.